• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Correction to "Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies".《司库奇尤单抗治疗伴或不伴甲氨蝶呤的银屑病关节炎患者的疗效和安全性：两项3期研究的52周结果》的勘误
ACR Open Rheumatol. 2025 Jul;7(7):e70086. doi: 10.1002/acr2.70086.
2
Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies.比美吉珠单抗治疗伴或不伴甲氨蝶呤的银屑病关节炎患者的疗效和安全性：两项3期研究的52周结果
ACR Open Rheumatol. 2024 Nov;6(11):720-731. doi: 10.1002/acr2.11727. Epub 2024 Jul 30.
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块型银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5.
6
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.生物制剂初治的活动性银屑病关节炎患者接受比美克珠单抗治疗：III 期、随机、安慰剂对照、活性对照 BE OPTIMAL 研究的 52 周疗效和安全性结果。
Ann Rheum Dis. 2023 Nov;82(11):1404-1414. doi: 10.1136/ard-2023-224431. Epub 2023 Sep 11.
7
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension period.在中度至重度斑块状银屑病患者中，比美吉珠单抗三年的疗效和安全性：BE RADIANT 3b期试验开放标签延长期的长期结果。
Br J Dermatol. 2025 Jan 25. doi: 10.1093/bjd/ljaf032.
8
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.依那西普和英夫利昔单抗治疗银屑病关节炎：系统评价与经济学评估
Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. doi: 10.3310/hta10310.
9
Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).非甾体抗炎药（包括阿司匹林和对乙酰氨基酚）在接受甲氨蝶呤治疗炎性关节炎（类风湿关节炎、强直性脊柱炎、银屑病关节炎、其他脊柱关节炎）患者中的安全性。
Cochrane Database Syst Rev. 2011 Nov 9(11):CD008872. doi: 10.1002/14651858.CD008872.pub2.
10
Effectiveness of Bimekizumab in Psoriatic Arthritis: A Multicenter Real-Life Study With Clinical and Ultrasound Evaluation in the Lazio Region, Italy.比美吉珠单抗治疗银屑病关节炎的疗效：意大利拉齐奥地区一项结合临床与超声评估的多中心真实世界研究。
Int J Dermatol. 2025 Jun 27. doi: 10.1111/ijd.17927.

本文引用的文献

1
Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies.比美吉珠单抗治疗伴或不伴甲氨蝶呤的银屑病关节炎患者的疗效和安全性：两项3期研究的52周结果
ACR Open Rheumatol. 2024 Nov;6(11):720-731. doi: 10.1002/acr2.11727. Epub 2024 Jul 30.

Correction to "Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies".

出版信息

ACR Open Rheumatol. 2025 Jul;7(7):e70086. doi: 10.1002/acr2.70086.

DOI:10.1002/acr2.70086
PMID:40631969
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12239507/
Abstract
摘要